IL6 and breast carcinoma: In contrast, IL-6 serum levels were increased in our breast cancer patients at baseline, compared to normal controls and raised further significantly after treatment with both taxanes, a finding that might point to a direct effect of taxanes on hepatocytes or enhancement of tumour-induced Th2-directed inflammatory reaction.